Reactive arthritis

Summary

Reactive arthritis (MONDO:0017376) is a disease and 12 clinical trials. Top therapeutic interventions include infliximab, interferon gamma-1a, and roxithromycin. A subtype of rheumatic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 100 000 (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 36
• Clinical trials: 12

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 100 000		Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

36 HPO clinical features (Orphanet curated; top 36 by frequency):

HPO ID	Term	Frequency
HP:0000509	Conjunctivitis	Very frequent (80-99%)
HP:0000962	Hyperkeratosis	Very frequent (80-99%)
HP:0001369	Arthritis	Very frequent (80-99%)
HP:0001386	Joint swelling	Very frequent (80-99%)
HP:0001387	Joint stiffness	Very frequent (80-99%)
HP:0001597	Abnormality of the nail	Very frequent (80-99%)
HP:0002014	Diarrhea	Very frequent (80-99%)
HP:0002754	Osteomyelitis	Very frequent (80-99%)
HP:0002829	Arthralgia	Very frequent (80-99%)
HP:0008391	Dystrophic fingernails	Very frequent (80-99%)
HP:0011107	Recurrent aphthous stomatitis	Very frequent (80-99%)
HP:0100543	Cognitive impairment	Very frequent (80-99%)
HP:0100686	Enthesitis	Very frequent (80-99%)
HP:0100773	Cartilage destruction	Very frequent (80-99%)
HP:0200039	Pustule	Very frequent (80-99%)
HP:0000988	Skin rash	Frequent (30-79%)
HP:0001101	Iritis	Frequent (30-79%)
HP:0002027	Abdominal pain	Frequent (30-79%)
HP:0002037	Inflammation of the large intestine	Frequent (30-79%)
HP:0002103	Abnormality of the pleura	Frequent (30-79%)
HP:0003419	Low back pain	Frequent (30-79%)
HP:0500006	Urethritis	Occasional (5-29%)
HP:0000010	Recurrent urinary tract infections	Occasional (5-29%)
HP:0000554	Uveitis	Occasional (5-29%)
HP:0000613	Photophobia	Occasional (5-29%)
HP:0001659	Aortic regurgitation	Occasional (5-29%)
HP:0001701	Pericarditis	Occasional (5-29%)
HP:0001824	Weight loss	Occasional (5-29%)
HP:0001945	Fever	Occasional (5-29%)
HP:0002093	Respiratory insufficiency	Occasional (5-29%)
HP:0002206	Pulmonary fibrosis	Occasional (5-29%)
HP:0003565	Elevated erythrocyte sedimentation rate	Occasional (5-29%)
HP:0011227	Elevated circulating C-reactive protein concentration	Occasional (5-29%)
HP:0012219	Erythema nodosum	Occasional (5-29%)
HP:0012317	Sacroiliac arthritis	Occasional (5-29%)
HP:0034438	Balanitis	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	reactive arthritis
Mondo ID	MONDO:0017376
EFO	EFO:0007460
MeSH	D016918
Orphanet	29207
DOID	DOID:6196
NCIT	C128332
SNOMED CT	129133005
UMLS	C0085435
MedGen	39047
GARD	0005693
MedDRA	10003267, 10038294
NORD	1650
Is cancer (heuristic)	no

Also known as: arthritis urethritica · Fiessinger-Leroy disease · Fiessinger-Leroy-Reiter syndrome · PIRA · polyarthritis enterica · post-infectious arthritis · post-infectious reactive arthropathy · reactive arthritis · Reiter syndrome · Reiter’s disease · Reiter’s syndrome · venereal arthritis

Disease family

This is a subtype of rheumatic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › reactive arthritis

Related subtypes (29): palindromic rheumatism, rheumatic pulmonary valve disease, lupus erythematosus, mixed connective tissue disease, Reye syndrome, Wissler syndrome, acroosteolysis dominant type, chondrocalcinosis 2, Gorham-Stout disease, rheumatoid arthritis, camptodactyly-arthropathy-coxa vara-pericarditis syndrome, juvenile idiopathic arthritis, sweet syndrome, dermatomyositis, IL10-related early-onset inflammatory bowel disease, unexplained long-lasting fever/inflammatory syndrome, myalgia-eosinophilia syndrome associated with tryptophan, rheumatic fever, intermittent hydrarthrosis, fibroblastic rheumatism, interstitial granulomatous dermatitis with arthritis, scleroderma, idiopathic juvenile osteoporosis, polymyalgia rheumatica, autoinflammatory syndrome, progeria-associated arthropathy, LAMA5-related multisystemic syndrome, rheumatic disease of mitral valve, isolated sternocostoclavicular hyperostosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

4 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Azithromycin	Phase 3
Rifampin	Phase 3
INTERFERON GAMMA-1B	Phase 2
Infliximab	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00244179	PHASE2	UNKNOWN	New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis
NCT04846010	PHASE1/PHASE2	UNKNOWN	Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
NCT05409196	PHASE1	COMPLETED	Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults
NCT04402086	Not specified	RECRUITING	Rheumatology Patient Registry and Biorepository
NCT04751396	Not specified	RECRUITING	Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT05960864	Not specified	NOT_YET_RECRUITING	Chinese Spondyloarthritis Inception Cohort (CESPIC)
NCT07329556	Not specified	NOT_YET_RECRUITING	Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
NCT00001375	Not specified	COMPLETED	The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis
NCT00621387	Not specified	COMPLETED	Study of Long-Term Antibiotic Treatment in Reactive Arthritis
NCT02498301	Not specified	COMPLETED	Trial Evaluating Chemoprophylaxis Against Travelers’ Diarrhea - Prevent TD
NCT05115370	Not specified	COMPLETED	Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
NCT05458531	Not specified	COMPLETED	Monitoring of Inflammatory Conditions

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INFLIXIMAB	4	1
INTERFERON GAMMA-1A	3	1
ROXITHROMYCIN	3	1
CHEMBL1235718	0	1
CHEMBL4127074	0	1